Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q1 2023 · 10-Q
Revenue$137.22M$137.22M+17.1% vs Q1 2022 Net Income-$30.80M-$30.80MN/M vs Q1 2022 EPS Diluted-$0.25-$0.25N/M vs Q1 2022 Gross Profit$54,814,000+43.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flow-$12,692,000N/M Free Cash Flowderived-$22,619,000N/M Margins · derivedGross margin39.9%+7.3 pt vs Q1 2022
Operating margin-25.6%+18.8 pt vs Q1 2022
Net margin-22.4%+19.7 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end